MiNK Therapeutics, Inc. (INKT)
NASDAQ: INKT · Real-Time Price · USD
10.77
+0.11 (1.03%)
Jul 20, 2026, 4:00 PM EDT - Market closed
MiNK Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
15
Market Cap
53.66M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xilio Therapeutics | 53.48M |
| Radiopharm Theranostics | 10.86M |
| Immutep | 5.28M |
| BeyondSpring | 1.88M |
| Cardiff Oncology | 525.00K |
| INmune Bio | 50.00K |
INKT News
- 4 weeks ago - MiNK Therapeutics Transcript: AGM 2026 - Transcripts
- 6 weeks ago - MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting - GlobeNewsWire
- 7 weeks ago - MiNK Therapeutics doses first patient in agenT-797 trial - TheFly
- 7 weeks ago - MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness - GlobeNewsWire
- 2 months ago - MiNK Therapeutics reports new data on agenT-797 at ATS 2026 - TheFly
- 2 months ago - MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications - GlobeNewsWire
- 2 months ago - MiNK Therapeutics Earnings Call Transcript: Q1 2026 - Transcripts
- 2 months ago - MiNK Therapeutics Earnings release: Q1 2026 - Filings